CCL18 and myeloid sarcoma: A focused sub-analysis in clinical phenotype groups showed that PC-CCL18 levels were correlated in RR-MS patients (rho = 0.29, p = 0.008, CI 95% = 0.08, 0.48) but not in progressive patients (rho = 0.23, p = 0.10, CI 95% = −0.04, 0.48).